Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma

Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?

(2014) I. Chevolet et al.   BRITISH JOURNAL OF DERMATOLOGY

Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors

(2014) Alexander Eggermont et al.   OncoImmunology

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid-derived suppressor cells in cancer: recent progress and prospects

(2013) Yazan S Khaled et al.   IMMUNOLOGY AND CELL BIOLOGY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer

(2013) J. Yu et al.   JOURNAL OF IMMUNOLOGY

Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification

(2013) Céline Berthon et al.   LEUKEMIA RESEARCH

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance

(2012) Theodore S. Johnson et al.   IMMUNOLOGICAL INVESTIGATIONS

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

(2012) Joannes FM Jacobs et al.   LANCET ONCOLOGY

Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth

(2012) Taku Fujimura et al.   OncoImmunology

Immune mediated mechanisms of melanocyte destruction

(2012) Reinhart Speeckaert et al.   OncoImmunology

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients

(2011) Reinhart Speeckaert et al.   EUROPEAN JOURNAL OF CANCER

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Identification of a Variable Number of Tandem Repeats Polymorphism and Characterization of LEF-1 Response Elements in the Promoter of the IDO1 Gene

(2011) Marion Soichot et al.   PLoS One

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms

(2009) J. C. Schefold et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Simultaneous measurement of tryptophan and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry

(2008) K YAMADA et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES